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Abstract 
Copy number gain of 8q24 is a common structural abnormality in human cancers. 
Although MYC is usually assumed to be responsible for 8q24 gain cancer, the role of the 
other genes in the 8q24 region remains mostly unknown. We derived chromosome 
engineered mice with an extra copy of Myc-Gsdmc region which is syntenic to the 
common region gained in human 8q24-associated cancer. These mice show aberrant 
differentiation and loss of proliferation arrest of mammary epithelial cells, excessive 
branching of mammary ducts, and increased sensitization to mammary tumors. In 
contrast, mice carrying a duplication of either Myc or Pvt1-Gsdmc were found to be 
insufficient for neoplasia. We show that the long non-coding RNA Pvt1 and adjacent Myc 
can co-operate in tumorigenesis. Furthermore, PVT1 can regulate MYC protein stability 
in human breast cancer cells. Our study reveals a novel mechanism of MYC regulation 
by a long non-coding RNA in cancer cells and could provide therapeutic targets.  
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Introduction and Literature Review 
Chromosomal aberration is a signature of cancer (Hanahan and Weinberg, 2000; 
Mitelman, 2005; Storchova and Pellman, 2004). Several chromosomal regions with 
increased/decreased copy numbers have been frequently identified across diverse human 
cancers by current genome scanning platforms, such as high resolution array-
Comparative Genomic Hybridization (aCGH) and Single Nucleotide Polymorphism 
(SNP) array (Aguirre et al., 2004; Carrasco et al., 2006; Tonon et al., 2005; Zhao et al., 
2005).  In addition, cancer clinical outcomes (Engler et al., 2012; Kim et al., 2012) and 
therapeutic treatment has been successfully predicted by large-scale DNA copy number 
variations (CNVs). A notable genomic event is chromosome 8q24 gain, which is 
frequently observed in many cancer types, including breast cancer (Horlings et al., 2010). 
In breast cancer, 8q24 gain is observed in over 20% of primary tumors and cell lines. 
Importantly, 8q24 gain is reinforced by its association with poor prognosis. While the 
well-established oncogene, MYC, maps to this region and likely contributes to the 
pathology of cancers, the long non-coding RNA, PVT1, also maps to this region and has 
been implicated in carcinogenesis in which it is co-amplified with MYC (Guan et al., 
2007; Huppi et al., 2012; TCGA, 2011, 2012a, b). However, an in vivo functional role of 
8q24 gain in cancer development remains a daunting challenge for lack of suitable animal 
models. Thus, in this study, we developed new chromosome engineered mouse models to 
accurately mimic human chromosome 8q24 gain in cancer and determine how this gain 
contributes to the initiation and progression of breast cancer.  
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Genomic mutations in cancers 
 Cancer is a genetic disease. For decades, scientists have identified many genomic 
mutations that influence key cellular pathways involved in carcinogenesis. These 
discoveries provide a solid foundation for understanding molecular mechanisms of tumor 
formation and developing better therapeutic strategies of cancer treatments. However, 
most research has focused on mutations, affecting the DNA sequence of genes. Little is 
known about the role of large-scale mutations in chromosomal structure, such as 
deletions and gains involving large spans of DNA. These structural mutations are a 
common occurrence in all forms of cancer (Beroukhim et al., 2010; Degenhardt et al., 
2008; Santarius et al., 2010). As such, an important aspect of functional genomic 
analyses in cancer is to faithfully recapitulate these structural mutations. Current mouse 
models have greatly improved our understanding of cancer, but the fact that the majority 
of mouse models are representative of sequence mutations leaves a gap in our 
understanding of the complexity of chromosomal aberrations. For example, a large-scale 
deletion or duplication region may alter the dosage of several tumor suppressor genes or 
oncogenes to collaboratively contribute the pathology of cancer. In such events, mouse 
models of single gene alteration are not suitable to address these structural mutations in 
cancer. Therefore, there is a need to generate mouse models that can mimic these 
penetrant mutations. Our goal is to closely mimic a chromosomal abnormality, gain of 
human 8q24 region, that has frequently been observed in the patients’ tumor by using 
mouse models, and to be able to understand the significance of 8q24 gain in the growth 
and development of the tumor.  
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Chromosome 8q24 region is associated with human cancers 
A gene desert located on human chromosome region 8q24.21 is particularly 
intriguing because of the complexity of the sequence variants and structural aberrations 
associated with 8q24 region in different cancer genomes. For example, genome wide 
association studies (GWAS) have identified several 8q24 single nucleotide 
polymorphisms (SNPs) linked to the development of breast cancer (Easton and Eeles, 
2008; Turnbull et al., 2010), prostate cancer (Gudmundsson et al., 2007; Turnbull et al., 
2010; Yeager et al., 2007), ovarian cancer (Ghoussaini et al., 2008; Goode et al., 2010; 
Yeager et al., 2007), colon cancer (Yeager et al., 2007), esophageal cancer 
(Gudmundsson et al., 2007; Lochhead et al., 2011; Yeager et al., 2007), bladder cancer 
(Ghoussaini et al., 2008; Kiemeney et al., 2008), chronic lymphocytic leukemia 
(Crowther-Swanepoel et al., 2010) and Hodgkin’s lymphoma (Enciso-Mora et al., 2010). 
Furthermore, the 8q24 region is one of the most common sites for human papilloma virus 
(HPV) integration in genital neoplasia (Ferber et al., 2003; Kraus et al., 2008; Peter et al., 
2006). In addition, the chromosomal 8q24-based translocation is a hallmark lesion in 
Burkitt’s lymphoma, large B-cell lymphoma, and T-cell leukemia (Erikson et al., 1983; 
Graham and Adams, 1986; Shtivelman et al., 1989; Webb et al., 1984). More 
importantly, gain of 8q24, such as duplication and amplification of 8q24 region, is also 
observed in numerous cancers, including 20% of breast cancer, 60% of ovarian, 25-40% 
of cervical cancers, 15-40% of prostate cancer, 42% of gastric cancers, 10-25% of 
melanoma, 7% of head and neck cancers, and 20% of lymphoma and leukemia.  (Borg et 
al., 1992; Boyd et al., 2012; Guan et al., 2007; Hartmann et al., 2008; Haverty et al., 
2009; Kim et al., 2006; Kraehn et al., 2001; Mangano et al., 1998; Treszl et al., 2004; van 
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Duin et al., 2007). Therefore, to fully understand the role of 8q24 in cancer development, 
it is important to investigate how this region contributes to cellular transformation. 
 
The role of 8q24 gains in cancer development is unclear 
A segment of 8q24 region linked to susceptibility for cancers is about 2.7 Mb 
(8q24.21, 128.0 Mb ~ 130.7 Mb) (Huppi et al., 2012). One gene found at this 8q24.21 
region, c-MYC (MYC) proto-oncogene, stands out as a key player in malignant 
transformation. For instance, in most of Burkitt’s lymphoma cases, the reciprocal 
chromosomal translocation is between the immunoglobulin (Ig) heavy chain and MYC. 
Deregulated MYC expression as a result of this fusion has been validated as an initiating 
step of Burkitt’s lymphoma development (Adams et al., 1985; Zhu et al., 2005). In 
addition, MYC activation that is triggered by the insertion of HPV DNA sequences has 
been reported to contribute cervical oncogenesis (Gurel et al., 2008; Peter et al., 2006). In 
the case of cancers with 8q24 gain, it was originally thought that increased copies of 8q24 
region simply lead to deregulated expression of MYC. However, inconsistent correlations 
between copy number variation (CNV) studies and gene expression analyses (Gurel et al., 
2008; Haverty et al., 2009) have raised the possibility that MYC is not the only factor. 
The question is, could other co-amplified genes on the 8q24 region be responsible for 
cancer development? Or, is MYC itself sufficient to drive pathogenesis of cancer? 
Comprehending the fact that increased 8q24 copy number is not equal to MYC 
overexpression is critical for finding a better therapeutic strategy to treat cancer patients 
with 8q24 gain. 
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 PVT1 locus is co-amplified with MYC 
With a study of high-resolution SNP array analysis, the hot zone of 8q24 copy 
number gains is around 2.1 Mb (8q24.21, 128.6 Mb ~ 130.7 Mb) including MYC, 
plasmacytoma variant translocation (PVT1), and CCDC26 (Haverty et al., 2009; Hirano 
et al., 2008; Huppi et al., 2012; TCGA, 2011, 2012a, b). Though an obvious candidate, 
the fact that copy-number increases of 8q24 frequently include MYC and the adjacent 
gene-desert, which may subsume additional genetic elements that contribute to induction 
of cancer is under-investigated. Adjacent to MYC is PVT1, a long non-coding (lnc) RNA 
locus originally identified as a cluster of breakpoints for viral integration and 
translocation in T- and B-cell lymphomas (Erikson et al., 1983; Webb et al., 1984). The 
PVT1 locus spans more than 300 kb that encompasses six microRNA-encoding 
sequences, miR-1204 ~ miR-1208 and is conserved in the human and mouse genomes 
(Beck-Engeser et al., 2008; Huppi et al., 2008). Despite being a mutational hotspot, the 
role of PVT1 in cancer is poorly understood. A recent cell culture-based study has 
suggested anti-apoptotic and pro-survival roles for PVT1 (Guan et al., 2007).  One of the 
miRNAs encoded by the PVT1 locus, miR-1204, has been reported to be enriched in 
8q24 gain-specific cancer cell lines (Beck-Engeser et al., 2008; Huppi et al., 2008), 
although another study has implicated miR-1204 with tumor suppressive activity 
(Barsotti et al., 2012). The lack of an in vivo system that links MYC with additional 
elements in the 8q24 region has been a major impediment in understanding the role of 
genetic elements in this region to the pathophysiology of cancer. 
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Breast cancer with 8q24 gain is associated with poor prognosis 
Breast cancer is second leading cause of cancer death in women. According to 
American Cancer Society’s statistics, one of every eight women in United State will 
develop invasive breast cancer during their lifetime. These statistics highlight the burden 
that breast cancer poses on the national healthcare system in particular and society in 
general. Recent advances in our understanding of breast cancer have resulted in 
improvement in the treatment and management of the disease; nevertheless, the 
development of more effective and targeted therapies for breast cancer patients remains a 
goal in the cancer community. Therefore, developing in vivo models that finely mimic the 
genetic alterations of breast cancer can not only explore basic pathophysiological 
mechanisms but also evaluate new therapeutic approaches.  
DNA copy-number gains, such as duplication and amplification, are common 
mutations found in epithelial cancers, including breast cancer. Around 20% breast 
cancers show increased copies of 8q24 region (Berns et al., 1992a; Letessier et al., 2006) 
and are associated with poor clinical outcomes (Aulmann et al., 2006; Berns et al., 1992a; 
Berns et al., 1992b; Bonilla et al., 1988; Deming et al., 2000; Roux-Dosseto et al., 1992; 
Schlotter et al., 2003). For example, 8q24 gain has been found in the more aggressive 
phenotype of ductal carcinoma in situ (Aulmann et al., 2002) or in only the invasive 
component (Aulmann et al., 2006; Corzo et al., 2006; Robanus-Maandag et al., 2003). 
PVT1 locus co-amplified with MYC in the 8q24 region and PVT1 transcripts have been 
implicated to participate in breast cancer progression as well (Guan et al., 2007). 
However, little evidence exists to support that role because most studies have 
concentrated on the oncogene, MYC. A clear functional role of 8q24 gain for breast 
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cancer pathophysiology still needs to be validated in vivo. Yet, most mouse models for 
breast cancer studies focus primarily on the effects of Myc overexpression in promoting 
mammary tumor formation (Boxer et al., 2004; D'Cruz et al., 2001; Schoenenberger et 
al., 1988; Stewart et al., 1984). For instance, the first transgenic Myc model, in which the 
oncogene was expressed under the control of the hormone responsive mouse mammary 
tumor virus (MMTV) promoter, developed mammary adenocarcinomas following their 
first pregnancy (Stewart et al., 1984). Subsequently, other transgenic models, including 
models in which Myc expression can be regulated (by Tet-on and Tet-off systems) have 
tried to elucidate the mechanisms by which deregulated MYC contributes to 
tumorigenesis, including regulatable tumors in the mammary tissue (Boxer et al., 2004; 
D'Cruz et al., 2001). Although these transgenic mouse models are very helpful in 
elucidating the role of MYC deregulation, no mouse model can truly recapitulate the 
increased copies of 8q24 region. To investigate the role of 8q24 gain in breast 
carcinogenesis, new approaches should be applied to improve current models. 
 
Chromosome engineered mouse models mimic human genetic diseases  
 Chromosomal aberrations are frequently found in humans and could be disease-
associated or phenotypically neutral. Validating the functional role of these aberrations 
and understanding how they contribute to the pathology of cancer are necessary for 
improvement in diagnosis and therapy. Because of genetic and physiologic similarities 
between mouse and human, mouse has proved to be an invaluable model organism in 
allowing understanding of the genomic landscape that results in human diseases. In 
addition, mice have many important advantages over other mammalian models, including 
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(1) small body size; (2) less expensive for maintaining; (3) fast reproduction and large 
litter size; (4) mature techniques for genetic manipulation. A novel method, chromosome 
engineering, which combines the power of gene targeting in mouse embryonic stem (ES) 
cells with Cre/loxP recombination, allows for the generation of mouse models that harbor 
large-scale rearrangements of specific chromosome regions (Mills and Bradley, 2001; Yu 
and Bradley, 2001). For example, the mouse models that were generated by chromosome 
engineering have several psychotic phenotypes similar to those seen in autism or 
schizophrenia patients with duplication of the 15q11-13 locus (Nakatani et al., 2009), 
deletion/duplication of the 16p11.2 (Horev et al., 2011), or microdeletion of the 22q11.2 
(Merscher et al., 2001; Stark et al., 2008). In addition to these psychiatric disorders, 
chromosome engineered mouse models with loss or gain of genomic regions 
corresponding to human 1p36 successfully provide functional evidence that 
chromodomain helicase DNA binding 5 (CHD5) plays a tumor suppressive role in caner 
development (Bagchi et al., 2007). Thus, chromosome engineering offers a very powerful 
tool to mirror the gain of human 8q24 region as closely as possible in the mouse genome. 
 
Her2 amplification is a common co-mutation with 8q24 gain in breast cancer  
Cancer is frequently accompanied by multiple genetic alterations. As previously 
mentioned 8q24 region has been reported to be amplified in approximately 20% of breast 
cancers and appears to related to a poor prognosis. The 17q12 region, contains human 
epidermal growth factor receptor 2 (HER2) gene, is highly amplified (more than 200 
copies) in around 30% of breast cancers and, therefore, leads to HER2 overexpression 
(Liang et al., 2008). Interestingly, many studies have reported that the 8q24 gain is 
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strongly associated with ERBB2/HER2/neu amplification in breast cancers (Al-Kuraya et 
al., 2004; Park et al., 2005; Persons et al., 1997; Sircoulomb et al., 2010). With 
cytogenetic analyses, for instance, more than 40% of 8q24 gain breast cancers co-
amplified with HER2 amplification (Janocko et al., 2001; Park et al., 2005; Persons et al., 
1997). Adjuvant ERBB2-targeted therapy, trastuzumab, improves the overall survival 
rate of ERBB2-positive early cancer patients compared with chemotherapy alone (Perez 
et al., 2009). However, clinical outcome findings are inconsistent regarding the benefits 
from adjuvant trastuzumab therapy in ERBB2/8q24 amplifications patients (Kim et al., 
2005; Perez et al., 2011). These indicate that several synergistic collaborations activate 
the ERBB2 pathway by increased copies of MYC or other gene deregulation, such as 
PVT1 locus, located on the 8q24 interval. It is important to identify these relationships to 
develop alternative molecular targets and manage combination therapies.  
 
Summary 
Chromosomal abnormalities like deletions, translocations, and 
duplications/amplifications are hallmarks of almost all cancers. Increased copy number of 
the 8q24 region, such as a single-copy gain of 8q24, a locus that contains the proto-
oncogene MYC, has been implicated in many human cancers, particularly in solid tumors. 
Importantly, this 8q24 gain is often associated with poor progonosis of breast cancer, 
indicating that 8q24 gain may not only play an important role in tumorigenesis but also 
contribute to tumor progression. Mouse models for studying the effects of Myc 
overexpression have been helpful in elucidating its in neoplastic transformation. 
However, these transgenic mouse models do not allow for examining the large-scale 
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genomic gain of 8q24 that is frequently found in human breast cancers, strongly 
suggesting the need for additional models to mirror the highly penetrant and aggressive 
tumors associated with 8q24 gain. Moreover, in many cancers, MYC is co-amplified with 
the neighboring genetic elements which have also been implicated in tumorigenesis in 
multiple studies. We argue that increased copies of MYC alone is not sufficient to result 
in the poor prognosis seen in the breast cancer patients with 8q24 gain, and we 
hypothesize that additional gene(s) in the 8q24 amplicon contributes substantially to the 
mammary tumor initiation and/or aggressive progression of neoplasia. 
In this study, we sought to determine the contributions of a single-copy gain of 
8q24 to oncogenic transformation in cancer. Our study focused on determining whether 
either gain of MYC alone is sufficient to drive tumor formation, or if other elements in the 
gene-desert region play a role in this process. To fully understand the role of 8q24 gain in 
cancer development, we developed genetically engineered mice with a single-copy 
number gain of an approximately 2 Mb interval that is syntenic to Hu 8q24.21. Next, to 
discern the contribution of Myc and the rest of region in cancer inception, we generated 
two additional genetically engineered mouse strains, one harboring a gain of Myc only 
and another with an extra copy of the rest of the region. Using these in vivo models and 
human breast cancer cell lines, we have uncovered a new oncogenic role for lncRNA 
PVT1, and demonstrate that it co-operates with MYC in oncogenic transformation. 
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Materials and Methods 
Chromosome Engineering 
The procedures of chromosome engineering were performed as previously described 
(Bagchi et al., 2007). In brief, AB2.2 ES cells (129S5 strain) were electroporated with 25 
µg of the targeting vector (Table 1). These electroporated ES cells were cultured in G418 
(180 µg/ml) or puromycin (3 µg/ml) for 7-10 days. Correctly targeted clones were 
identified by polymerase chain reaction (PCR) analysis. Double-targeted ES cells were 
electroporated with the transient Cre recombinase expression vector pOG231. After 
subsequent selection of recombinants by using hypoxanthine aminopterin thymidime 
(HAT) media for 7 days and then recovery of recombinants by using hypoxanthines and 
thymidine (HT) media for 2 days, the H
R
G
R
P
R
 clones containing one mouse chromosome 
15 with the targeted locus duplication (dp) and the other mouse chromosome 15 with the 
targeted locus deletion (df) were identified and confirmed by using fluorescence in situ 
hybridization (FISH) analysis. 
 
Mouse Strains and Tumor Analysis 
Correctly targeted df/dp ES clones were injected into C57BL/6J blastocysts to establish 
chimeric mice. The F1 dp/+ progeny generated from chimera crossed with C57BL/6J 
were genotyped by PCR and backcrossed three times to FVB/N mice. For tumor analysis, 
dp/+ mouse strains were crossed with FVB/N-Tg(MMTVneu)202Mul/J transgenic mice 
(purchased from The Jackson  
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Table 1. Gene targeting of mouse genome at the Myc
L
, Myc
R
 and Gsdmc
R
 loci. 
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Laboratory) to generate the control (hemizygous MMTVneu) and experimental (dp/+, 
hemizygous MMTVneu) animals. After 4 months, these mice were monitored weekly by 
palpation for tumor induction. Tumors were documented in a double blinded manner. 
Animal protocols were approved by the Institutional Animal Care and Use Committee of 
University of Minnesota and were conducted in accordance with the procedures in the 
Guide for Care and Use of Laboratory Animals. 
 
Mammary Gland Isolation, Whole Mounts, and Measurement of Mammary 
Ductal Branching 
Six-week-old and ten-week-old virgin mice were sacrificed for dissecting mammary 
glands. Mammary glands from at least three mice per genotype were analyzed. For the 
mammary ductal branching studies, inguinal (No. 4) mammary glands were spread out, 
fixed in 4% paraformaldehyde (Merck) for 2 hr, and then stained as described 
(Schwertfeger et al., 2006).  Images were acquired using Lieca Application Suite 
software on a Leica dissecting microscope and analyzed using Adobe Photoshop and 
ImageJ software. Number of ductal branch point was measured from the 25 mm
2
 area 
near the lymph node of mammary gland. All experimental mice and control mice were 
littermates with matching estrous cycles.  
 
Histological Analysis and Tissue Immunofluorescence Staining 
Histological analyses were performed on hematoxylin and erosin (H&E)-stained paraffin 
sections of paraformaldehyde-fix (4%) mammary glands and tumors. For 
immunofluorescence analyses, 5-µm sections were deparaffinzed and rehydrated, and 
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antigens were retrieved using the Antigen Unmasking Solution (Vector Laboratories). 
Section samples were washed with PBS and blocked using M.O.M. basic kit (Vector 
Laboratories) or 10% normal goat serum for 1 hr. Primary antibodies were incubated for 
overnight at 4 ⁰C. For proliferation assays, mice were injected with 100 mg/kg BrdU 
drug (Sigma) 2 hr before sacrifice, and tissues were stained with anti-BrdU (Abcam) at 
1:300 dilution as described previously [Reed et al., 2012], and sections were counter 
stained with diaminophenylindole (DAPI, Invitrogen). Other primary antibodies were 
diluted with M.O.M. diluent as the following conditions: cytokeratin 8 (1:100, 
Epitomics), cytokeratin 14 (1:150, Covance), ERα (1:50, Santa Cluz Biotechnology), and 
γH2AX (1:100, Cell Signaling). Each staining was performed in mammary gland sections 
dissected from at least three mice of experimental groups and control group. Fluorescent 
images were acquired using the fluorescence microscopy (Carl Zeiss Axio 
Obersever.Z1). 
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Cell Culture and Reagents 
Primary mouse tumor cells or primary mouse mammary epithelial cells (MECs) were 
dissociated from mammary tumors or mammary glands by incubation with collagenase 
type I (Invitrogen) for 3 hr and then plated on fetuin (Sigma) in growth media 
(DMEM/F12 containing 10% fetal bovine serum (FBS, Gibco), 5 µg/ml insulin (Sigma), 
1 µg/ml hydrocortisone (Sigma), 5 ng/ml EGF (Sigma), and 200U/ml pen/strep 
(Invitrogen)) as described previously [Schwertfeger et al., 2006]. After 3 days, mammary 
epithelial cells and tumor cells were collected and stored at -80 ⁰C for further 
experiments. Only early passages of tumor cells were used for advanced assays. Human 
breast cancer cell lines SK-BR-3 and MDA-MB-231 were obtained from American Type 
Culture Collection (Manassas, VA). SK-BR-3 and MDA-MB-231 cells were cultured in 
McCoys5A (Lonza) containing 10% FBS and DMEM (Invitrogen) containing 10% FBS 
individually.  
 
RNA Isolation, Reverse-Transcription, and RT-qPCR Analysis 
Mouse mammary glands were removed at six and ten weeks of age and immediately 
stored in the liquid nitrogen. Frozen mammary tissue lysates were prepared in Trizol 
Reagent (Invitrogen) by using the SHREDDER SG3 system (Pressure BioSciences Inc.) 
as described by manufacturer. Cell lysates were collected from 6-well plates. RNA was 
isolated from the Trizol Reagent (Invitrogen), including a DNase digestion step (Qiagen), 
as described by manufacturer. Total RNA was quantified by NanoDrop (Thermo Fisher). 
RNA quality was estimated by running RNA on agarose gels. cDNA was synthesized 
from equal amounts of total RNA and followed the manufacturer’s protocol using 
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SuperScript III reverse transcriptase (Invitrogen) with Random Hexamer primers. For 
real-time quantitative PCR (RT-qPCR), the 50 ng of cDNA was added in reactions 
carried out on an ep realplex S machine (Eppendorf) using SyberGreen master mix 
(Promega) and gene-specific primers (Table 2). Primers for all amplification were 
designed the location on exon-exon borders by using Primer3 software. Melting curve 
analysis was performed to confirm the specificity of primers. Amplifications were 
performed as technical duplicates and biological triplicates in 96-well plates.  
  
Western Analysis 
Mouse mammary tissues were collected as above and protein extracted by using the 
SHREDDER SG3 system (Pressure BioSciences Inc.) in RIPA lysis buffer (50 mM Tris-
HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% Triton-X-100; 0.5% sodium deoxycholate; 
0.1% SDS) with Complete Protease Inhibitor Cocktail (Roche Applied Science). Cell 
lysates were also prepared in RIPA lysis buffer at the indicated time points. Lysates were 
centrifuged 14,000 rpm at 4 ⁰C for 30 min, supernatants were collected, and protein was 
quantified with the Bio-Rad protein assay kit. Equal amounts of protein were loaded and 
analyzed by SDS-PAGE. Immunoblotting was done using the following antibodies 
purchased from Cell Signaling, unless noted: c-Myc (Abcam), GAPDH, pERK1/2, 
ERK1/2, and P53. The signal intensity for protein of interest was normalized to that of 
GAPDH. 
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Table 2. Oligonucleotide sequences. 
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siRNA Transfections and 3D Culture 
siRNA against human PVT1 and c-MYC as well as mouse Pvt1 and c-Myc were designed 
and purchased from FlexiTube siRNA (Qiagen). Two siRNAs located different parts of 
PVT1/Pvt1 mRNA sequence (Hs_PVT1_5 FlexiTube siRNA and Hs_PVT1_6 FlexiTube 
siRNA; Mm_Pvt1_1 FlexiTube siRNA and Mm_Pvt1_4 FlexiTube siRNA) and two 
siRNAs located different parts of MYC/Myc mRNA sequence (Hs_MYC_5 FlexiTube 
siRNA and Hs_MYC_7 FlexiTube siRNA; Mm_Myc_1 FlexiTube siRNA and 
Mm_Myc_4 FlexiTube siRNA) were used in this study. A predesigned siRNA (AllStars 
Neg. siRNA, Qiagen) were used for the negative control and conjugated with Alex-488 to 
confirm the transfection efficiency. Approximately 2 x 10
5
 cells were plated to each well 
of a 6-well plate 24 hr before the transfection procedure and the cell confluency of each 
well were 50%. siRNA transfection was applied with DharmaFECT 4 (Thermo 
SCIENTIFIC) following the manufacturer’s protocol. Cells were harvested for RNA 
isolation 48 hr after transfection and for protein extraction 72 hr after transfection. 5 µM 
siRNA were tranfected into cells. Each experiment was repeated at least three times. For 
the ki67 proliferation assay, cells were trypsinized from the well of a 6-well plate 24 hr 
after transfection, and 1 X 10
4
 cells were replated in the three-dimensional (3D) on-top 
culture system to grow for 72 hr. For the 3D culture procedure, a total 1 X 10
4
 cells were 
plated on growth-factor reduced matrigel (BD Bioscience) in the 8-well chamber slide as 
described previously (Lee et al., 2007). MECs were maintained in growth media with 2% 
matrigel for observing the morphology of acinus-like structures and measuring the size of 
acinus-like structures. 
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Determination of Protein Stability 
Cells were separately transfected with the siRNA of PVT1 and negative control. After 24 
hours siRNA transfection, the cells of each transfection group were treated with 10 µM 
cycloheximide (Sigma) at 0 (control sample), 15, 30, 45, 60 minutes for protein stability 
analysis. Cells were harvested in RIPA lysis buffer at indicated time points. The cell 
lysates (20 µg) were then applied to Western analysis to determine the MYC and 
GAPDH proteins. Protein intensities were quantified using ImageJ software. The 
densitometric result of MYC protein of each time point was normalized to its 
densitometric result of GAPDH protein. The ratio of MYC protein intensities to their 
internal controls were then divided by the ratio of MYC protein intensity to its internal 
control of control sample. Each experiment set was repeated at least three times. 
 
Ki67 Proliferation Assay  
Cell proliferation assays were performed in breast cancer cell lines as previously 
described (Kenny et al., 2007; Lee et al., 2007). In brief, cells were directly fixed in 8-
well chamber slides with 4% paraformaldehyde after 96 hr siRNA treatments. Cells were 
blocked and stained with ki67 antibody (1:500, Vector Laboratories) and then 
counterstained with DAPI for the total number of cells as described previously (Lee et al., 
2007). Ki67 index was assessed by counting the proportion of ki67 positive cells. The 
number of ki67 positive cells were divided by the total number of cells. The number of 
total nuclei counted per well was above 500 for each experimental assay.  
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Statistical Analysis 
For Kaplan-Meier survival curves, statistical analyses were performed by using Prism 4 
(GraphPad Software), and p values were calculated by the log-rank test. All other p 
values were calculated using Student’s t test (unpaired, two-tailed, p < 0.05 was 
considered significant). Results are reported as mean ± SEM or mean ± SD. All 
experiments were performed at least three times. 
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Results 
Generation of Mouse Strains with ~2 Mb Rearrangements Corresponding to 
Human 8q24.21 
We sought to develop an in vivo system to elucidate the functional consequence 
of 8q24 gain in human cancer. Chromosome engineering of the mouse genome (Ramirez-
Solis et al., 1995) was carried out to develop strains with gain and loss of the mouse 
genomic interval syntenic to Hu 8q24.21 (Ch8:128,718,315 to Ch8:130,831,134). This 
corresponds to an approximate 2Mb region on Chr15 in mouse from Ch15:61,954,800 
(Myc
L
) to Ch15:63,944,470 (Gsdmc
R
) (Figure 1A). The Myc-Gsdmc interval is also a 
gene-desert region in the mouse. The highly conserved genomic synteny included 
annotated genes Myc, PVT1 and GSDMC as well as other unannotated genomic elements 
(Figure 1B, Appendix A). Six cancer-related risk alleles have been identified in the Myc-
Gsdmc region: rs2608053, rs2019960 (Enciso-Mora et al., 2010), rs1516982, 
rs10088218, rs10098821 (Goode et al., 2010) and rs55705857 (Jenkins et al., 2012). 
Syntenic homology for four out of these six risk alleles, rs2019960, rs1516982, 
rs10088218 and rs55705857, are found in the Myc-Gsdmc interval in the mouse (Figure 
1B, Table 3). The PVT1 locus also encodes five conserved miRNAs, miR-1204 – miR-
1208 (Figure 1B, Table 3) (Beck-Engeser et al., 2008; Huppi et al., 2008). A putative 
transcript, CCDC26, is suspected to be involved in several malignancies (Jenkins et al., 
2012). Though  
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Figure 1 A. The sytenic region of Hu 8q24.21 is at Mus chromosome 15. 
A ~ 2Mb genomic interval encompassing MYC-GSDMC on human 8q24.21 corresponds 
to a genomic region on mouse Chromosome 15 between D15Mit27-Mit103.  
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Figure 1 B. Genes and other structural features conserved between human and 
mouse in the Myc-Gsdmc interval. 
See Table 3 and Appendix A for details. Cancer related risk alleles 
(SNPs): rs2608053 ( ), rs2019960 ( ), rs1516982 ( ), rs10088218 ( ), rs10098821 ( ) and 
rs55705857 ( ), miRNAs: miR-1204 ( ), miR-1205 ( ), miR-1206 ( ), miR-1207 ( ) and 
miR-1208 ( ) and putative transcript CCDC26 map in this region. 
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Table 3. Genetic elements shared between human and mouse in the MYC-GSDMC 
interval. 
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a mouse homolog is yet to be identified, the genomic synteny is found to be conserved 
between the two species (Figure 1B, Table 3). These shared features indicate that the 
Myc-Gsdmc gene-desert is highly conserved between human and mouse. 
Gene targeting was performed in AB2.2 mouse embryonic stem (ES) cells 
deficient in hypoxanthine guanine phosphoribosyl transferase (Hprt). The targeting 
vectors were obtained from the Mutagenic Insertion and Chromosome Engineering 
Resource (MICER) and were modified to facilitate detection of correctly targeted clones 
by Polymerase Chain Reaction (PCR) (Table 1). Targeting at Gsdmc
R
 (distal to Gsdmc) 
(Figure 1C), occurred with a frequency of 12%. Germline-competent singly targeted 
clones were re-targeted at Myc
L
, proximal to Myc (Figure 1D, Table 1), with an efficiency 
of 26%.  Twelve doubly targeted ES cell clones were electroporated with a Cre-
expressing construct and the clones were grown under HAT selection for recombined 
alleles (Figure 1E). To confirm the genomic rearrangements, we examined these ES cells 
by fluorescent in-situ hybridization (FISH) using bacterial artificial chromosome (BAC) 
probes. These probes which are specific for mouse Ch15 centromeric region (RP23-
18H8) and the Myc-Gsdmc interval (RP24-78D24) affirmed the deficiency/duplication 
(df/dp) status of the Myc-Gsdmc interval in metaphase and interphase spreads (Figure 
1F). Two independent df/dp clones were established as mouse strains (Figure 1G) and the 
offspring were genotyped by PCR. Each strain was backcrossed to the FVB background 
for three generations. 
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Figure 1 C. First gene targeting at D15Mit103 locus. 
Gene targeting at D15Mit103 resulted in integration of a loxP site (triangle), a neomycin 
resistance cassette (N), the 5’ half of the hprt locus (5’), and the Tyrosinase gene (Ty) at 
the endogenous (wild-type, wt) D15Mit103 locus (upper). Targeting was assessed by 
PCR analysis of G418-resistant (G
R
) clones by using the primers specific for the gap and 
the targeting vector (see Table 2 for primers); a 3.7 kb or 3.3 kb PCR fragment is 
diagnostic for singly targeted (st) clones (lower).  
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Figure 1 D. Second gene targeting at D15Mit27 locus. 
Gene targeting in the st clone shown in (C) was performed to modify endpoint D15Mit27 
to yield doubly targeted (dt) clones. Only the Trans-targeting event (in which both 
targeting events occur on different homologs) is shown here. The loxP site, a puromycin 
resistance cassette (P), the 3’ half of the hprt locus (3’), and an Agouti transgene (Ag) 
were integrated at the D15Mit27 locus (upper). Accurate targeting of puromycin-resistant 
(P
R
) clones was assessed by PCR using the gap and vector specific primers (See Table 2 
for primers): a 5.6 kb or 3.6 kb PCR fragment is diagnostic for dt clones (lower). 
  
 28 
 
 
 
Figure 1 E. Cre-mediated recombination. 
Trans-targeted dt clones generated hypoxanthine aminopterin thymidine (HAT)-resistant 
(H
R
), G
R
, P
R
 df/dp clones. 
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Figure 1 F. FISH analysis of Myc-Gsdmc
df/dp
 ES cells. 
Metaphase and interphase preparations from the engineered cells were probed with BAC 
clone specific for Chromosome 15 and located outside (RP23-18H8, red) and within 
(RP24-78D24, green) the engineered region. The alleles containing the deletion and the 
duplication are marked. 
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Figure 1 G. Germline transmission of engineered allele. 
Germline transmission determined by PCR specific for Myc-Gsdmc
df/+
 and Myc-
Gsdmc
dp/+
 alleles. 
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Single Copy Gain of Myc-Gsdmc Affects Mammary Structure, Proliferation 
and Differentiation 
To determine how the copy number of the Myc-Gsdmc interval affected the 
morphogenesis of primary mammary epithelial cells (MEC), we isolated these cells from 
6 week-old-virgin Myc-Gsdmc
df/+
, wild type (wt), and Myc-Gsdmc
dp/+
 mice and cultured 
them in recombinant basement membrane (Matrigel
TM
). When normal epithelial cells are 
grown in a three dimensional (3D) Matrigel
TM
 environment, they form acinar structures 
that are characteristic of glandular development (Debnath and Brugge, 2005). During 
acinar development, a co-ordinated series of events involving cellular proliferation, 
apoptosis, and growth arrest results in an organized outer layer of quiescent epithelial 
cells surrounding a hollow luminal core (Mailleux et al., 2008; Reginato et al., 2005). We 
observed that the Myc-Gsdmc
dp/+
 cells formed larger acinar structures, while those from 
Myc-Gsdmc
df/+
 were smaller compared to the wild type acini after seven days of culture 
(Figure 2A-a), suggesting that the size of the acinar structures correlated with the dosage 
of Myc-GsmdC region. We further determined that the increase in acinar size in the Myc-
Gsdmc
dp/+
 MECs was due to increased cell-number and not due to cell-volume by 
counting the number of nuclei per structure after staining the acini with 4,6-diamidino-2-
phenylindole (DAPI). Statistical analysis using two-way analysis of variance (ANOVA), 
demonstrated that acinar structures derived from Myc-Gsdmc
dp/+
 MEC have significantly 
increased number of cells compared to the wild type, while the structures derived from 
Myc-Gsdmc
df/+ 
MECs have fewer cells (Figure 2A-b).  
 a 
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Figure 2 A. Mammary epithelial cells isolated from Myc-Gsdmc
dp/+
 mice promote 
proliferation in 3D Matrigel cultures.  
Equal amount of Myc-Gsdmc
df/+
, wt, and Myc-Gsdmc
dp/+
 mammary epithelial cells were 
grown for 14 days in 3D Matrigel cultures. (a) DIC images were taken at day 3 (top 
panel), day 7 (middle panel), and day 10 (bottom panel). The diameter of each acinar 
structure was measured at indicated time points. n=24, Error bars represent SE. *, P < 
0.05. (b) Confocal images of day 10 acinar structures stained with DAPI to monitor 
nuclei (left panel). Number of nuclei per acinus was quantified for acini formed by Myc-
Gsdmc
df/+
, wt, and Myc-Gsdmc
dp/+
 cells (right panel). Blue line, median value. Spread, 
1.5 times the interquartile range. *, P < 0.05. Note that Myc-Gsdmc
dp/+
 mammary 
epithelial cells grown in 3D Matrigel cultures show increased acinar structure size (a) and 
increased cell number per acinar structure (b). 
b 
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These observations led us to hypothesize that gain of a single copy of Myc-Gsdmc 
can alter the cellular features of the mouse mammary gland which subsequently leads to 
malignancy. These features include common molecular links shared between mammary 
development and tumorigenesis, such as branching morphology of mammary ducts, 
cellular proliferation and differentiation of post-puberty quiescent MECs at steady state. 
Mouse mammary development involves three distinct stages. At the newborn stage, a few 
mammary ducts occupy a small portion of the mammary fat pad. During puberty (4-9 
weeks old), rapid cellular proliferation of MECs results in lateral branching and ductal 
elongation at the sites of terminal end buds (TEB) which fill up the mammary fat pad 
(Watson and Khaled, 2008). Later, the TEBs disappear and the ducts enter a quiescent 
stage in virgin female mice until pregnancy. Aberrations in this cycle of mammary 
development have been observed in mouse models predisposed to mammary tumors 
(Medina, 2002). For example, MMTV-Wnt1 transgenic mice and those with conditional 
inactivation of PTEN in mammary epithelium show increased lateral branching of 
mammary ducts and excessive proliferation of MECs, leading to mammary tumorigenesis 
with reduced latency (Tsukamoto et al., 1988, Li et al 2002). To investigate the effect of a 
gain of the Myc-Gsdmc region on branching morphology of mammary ducts, we 
performed whole-mount analyses of the inguinal mammary glands from Myc-Gsdmc
dp/+
 
and their wild type littermates with matching estrous cycles. Mammary glands from ten-
week-old virgin female Myc-Gsdmc
dp/+
 mice exhibited increased lateral branching 
compared to wild-type (Figure 2B). We observed a 150% increase in  
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Figure 2 B . Excessive lateral branching in Myc-Gsdmc
dp/+
 mammary glands. 
Whole mount analysis of mammary glands from 10 weeks old wild type (wt) and Myc-
Gsdmc
dp/+
 littermates. Myc-Gsdmc
dp/+
 mammary glands have excessive lateral branching 
of mammary ducts (n=3). Quantification of ductal branch points per 25 mm
2
 area shown 
as bar graph. Data are presented as mean ± standard error (SE). Significance at *p < 0.05, 
**p < 0.01 and, ***p <0.001 using two-tailed Student’s t-test. LN, lymph node. 
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the lateral branch points within a 25 mm
2
 area near the lymph node of the Myc-Gsdmc
dp/+
 
mammary glands compared to the wild type ones. Moreover, analysis of hematoxylin and 
eosin (H&E) stained sections of the mammary glands from Myc-Gsdmc
dp/+
 mice revealed 
a precocious alveolar-like phenotype that was not observed in the  wild-type mice (Figure 
2C), indicating aberrant proliferation and differentiation of the Myc-Gsdmc
dp/+
 MECs. To 
assess whether Myc-Gsdmc gain affected proliferation in MECs, we carried out 
bromodeoxyuridine (BrdU) incorporation analysis on glands from Myc-Gsdmc
dp/+
 and 
their wild-type littermates. At 10 weeks of age, the MECs of virgin mice undergo relative 
replicative quiescence. Interestingly, we observed a greater number of BrdU-positive 
nuclei in ducts of Myc-Gsdmc
dp/+
 mice compared to the wild-type (Figure 2D). More than 
11.3% (± 1.7) of the MECs from Myc-Gsdmc
dp/+
 mice had BrdU-positive epithelial 
nuclei compared to 0.6% (± 0.1) in the wild-type mice (Figure 2D, n ≥ 3). These data 
suggest that a single-copy gain of Myc-Gsdmc leads to loss of proliferation arrest in the 
mammary epithelium of adult virgin mice. 
To assess the effect of a gain of Myc-Gsdmc on the differentiation of the 
mammary epithelial cells, we carried out immunofluorescence studies using antibodies 
against specific mammary epithelial markers. The mouse mammary duct is defined by 
myoepithelial cells forming the outer layer while luminal cells constitute the inner layer 
(Tiede and Kang, 2011). Therefore, we examined the differentiation status of the cells in 
the mammary ducts from 10-week-old wild type and Myc-Gsdmc
dp/+
 littermates by 
detecting the luminal marker keratin-8 (K8) and myoepithelial marker keratin-14 (K14). 
While the epithelium from wild- 
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Figure 2 C. Precocious alveolar-like phenotype in Myc-Gsdmc
dp/+
 mammary ducts. 
H&E staining of the mammary ducts from wt and Myc-Gsdmc
dp/+
 mice revealed 
precocious alveolar-like phenotype in the latter. The aberrant structure is shown at higher 
magnification in the bottom row. 
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Figure 2 D. Loss of proliferation arrest in Myc-Gsdmc
dp/+
 mammary glands. 
BrdU incorporation assay in the mammary ducts of wt and Myc-Gsdmc
dp/+
 littermates. 
BrdU-positive cells is shown in red. DAPI, used as a counterstain, is shown in blue. The 
percentage of BrdU-positive cells of ducts shown as bar graph. The values represent the 
average fraction of BrdU-positive epithelial cells per total number of epithelial cells of 
three different mice. Data are presented as mean ± standard error (SE). Significance at *p 
< 0.05, **p < 0.01 and, ***p <0.001 using two-tailed Student’s t-test. 
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type mice exhibited an expected outer layer of myoepithelial cells (K14 positive) and an 
inner layer of luminal cells (K8 positive), a number of luminal cells in the Myc-Gsdmc
dp/+ 
mammary ducts were found to express myoepithelial (K14) markers, suggesting mis-
expression of myoepithelial markers in Myc-Gsdmc
dp/+ 
luminal cells (Figure 2E). 
Strikingly, we observed multiple layers of luminal cells that filled the Myc-Gsdmc
dp/+
 
ducts (Figure 2E). To detect whether Myc-Gsdmc gain contributed to proliferation of 
myoepithelial and luminal cells, we co-stained the sections with antibodies against BrdU 
and K14.  BrdU-positive signals were observed in both luminal and myoepithelial cells 
(Figure 2F). Because ERα-positive MECs are known not to undergo cell division 
(Lamote et al., 2004), we examined the number of ERα-positive MECs in Myc-Gsdmcdp/+ 
and wild type mammary ducts. Consistent with the higher level of cellular proliferation 
observed in Myc-Gsdmc
dp/+
 mammary epithelium, only 9.9% (± 1.2) Myc-Gsdmc
dp/+
 
MECs were ERα-positive (Figure 2G) compared to wild type. Taken together, these data 
indicate that an extra copy of Myc-Gsdmc can confer aberrant proliferation and 
differentiation of mammary epithelium in vivo. 
 
Generation of Myc
dp/+
 and Pvt1-Gsdmc
dp/+
 mice 
The Myc-Gsdmc
dp/+ 
mice fulfilled the need of a suitable animal model that mimics 
the copy-number gain of 8q24, and thus addresses its role in cancer. To investigate if Myc 
is the only gene that contributes to the aberrant phenotypes  
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Figure 2 E. Aberrant differentiation of mammary epithelial cells in Myc-Gsdmc
dp/+
 
mice. 
Immunofluorescence co-staining for luminal marker K8 (red) and myoepithelial marker 
K14 (green) in mice. Arrowheads indicate co-expression of K8 and K14. 
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Figure 2 F. Excessive proliferation of myoepithelia cells and luminal cells in Myc-
Gsdmc
dp/+
 mammary ducts. 
Color merged images of multi-labeled immunofluorescence fixed mammary ducts of wt 
and Myc-Gsdmc
dp/+
 mice. Antibodies used against K14 (green) and BrdU (red). DAPI 
stained nuclei in blue. Arrowheads indicate co-localization of BrdU and K14 in Myc-
Gsdmc
dp/+
 mammary ducts. 
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Figure 2 G. Reduced expansion of ERα+ cells in Myc-Gsdmcdp/+  mammary ducts. 
Immunofluorescence analysis of ERα (green) on sections of mammary ducts. Cell nuclei 
positive for ERα were counted and the numbers were expressed as the percentage of total 
epithelial cell nuclei (DAPI, blue). Results are mean ± SD of nine determinations for each 
of three individual mammary tissues. Images shown are representative 3 mice per 
genotype. 
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observed in Myc-Gsdmc
dp/+ 
mammary gland, or if it collaborates with other gene(s) in the 
Myc-Gsdmc interval, we generated additional mouse strains. We employed chromosome 
engineering of mouse ES cells to develop mouse strains containing an additional copy of 
Myc (Myc
dp/+
) and Pvt1-Gsdmc (Pvt1-Gsdmc
dp/+
, Figure 3A). To develop ES cells with 
balanced rearrangement of the Myc locus (Myc
df/dp
), gene-targeting was first carried out at 
ch15: 61,990,555 (Myc
R
) distal to Myc (Figure 3B). Correctly targeted clones were 
identified by PCR analysis. Singly targeted, germline competent clones were retargeted at 
Myc
L
, proximal to Myc gene. A dozen, doubly targeted clones were subjected to transient 
Cre-expression, as described before. Clones resistant to G418, puromycin and HAT were 
identified as Myc
df/dp
 clones and further confirmed by PCR.  Chimeras were derived from 
two independent Myc
df/dp
 clones. Germline transmission of the Myc
dp/+
 allele was 
obtained by crossing the chimeras with wild type females. The Myc
dp/+
 were crossed to 
FVB wild-type mice for three subsequent generations. A similar procedure was employed 
to obtain Pvt1-Gsdmc
dp/+
 mice (Figure 3C). 
 
Gain of Myc or Pvt1-Gsdmc Alone is Insufficient to Produce Aberrant 
Phenotype in Mammary Epithelium 
 Our central objective is to functionally validate whether Myc co-operates with 
other genes in the Hu 8q24.21 locus for neoplastic transformation in breast cancer. If so, 
we expect that neither Myc
dp/+ 
nor Pvt1-Gsdmc
dp/+ 
should develop the aberrant 
phenotypes seen in Myc-Gsdmc
dp/+ 
mammary glands. To test this hypothesis, whole 
mounts of mammary glands from Myc
dp/+ 
and Pvt1-Gsdmc
dp/+ 
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Figure 3 A. Chromosome engineered mouse for a single copy gain of Myc or Pvt1-
Gsdmc.  
Schematic of three chromosome engineered mouse strains: Myc-Gsdmc
dp/+
, Pvt1-
Gsdmc
dp/+
 and Myc
dp/+
 (See Figure 3B and 3C and Table 1 for details). 
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Figure 3 B. Engineering Myc
df/dp
 allele in mouse ES cells. 
(a) Gene targeting at c-Myc
R
 resulted in integration of a loxP site (triangle), a puromycin 
resistance cassette (P), the 3’ half of the hprt locus (3’), and an Agouti gene (Ag) at the 
endogenous locus (upper). Targeting was assessed by PCR analysis of Puromycin-
resistant clones by using the primers specific for the gap and the targeting vector (see 
a 
b 
c 
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Table 2 for primers); a 5.2 kb or 3.2 kb PCR fragment is diagnostic for singly targeted 
(st) clones (lower). (B) Gene targeting in the st clone was performed at Myc
L
 to yield 
doubly targeted (dt) clones. Only the Trans-targeting event is shown here. The loxP site, 
a neomycin resistance cassette (N), the 5’ half of the hprt locus (5’), and a Tyrosinase 
transgene (Ty) were integrated at the Myc
L
 locus (upper). Accurate targeting of G418-
resistant clones was assessed by PCR using the gap and vector specific primers (See 
Table 2 for primers):  a 5.6 kb or 3.6 kb PCR fragment is diagnostic for dt clones (lower). 
(C) Cre-mediated recombination. trans-targeted dt clones generated hypoxanthine 
aminopterin thymidine (HAT)-resistant (H
R
), G
R
, P
R
 df/dp clones. 
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Figure 3 C. Engineering Pvt1-Gsdmc
df/dp
 allele in mouse ES cells. 
(a) Gene targeting at Myc
R
 discussed in Figure 3B-a. (b) Gene targeting in the c-Myc
R  
targeted clone was performed at Gsdmc
R
 to yield doubly targeted (dt) clones. Only the 
a 
b 
c 
 47 
 
Trans-targeting event is shown here. The loxP site, a neomycin resistance cassette (N), 
the 5’ half of the hprt locus (5’), and a Tyrosinase transgene (Ty) were integrated at the 
Gsdmc
R
 locus (upper). Accurate targeting of G418-resistant clones was assessed by PCR 
using the gap and vector specific primers (See Table 2 for primers):  a 3.7 kb or 3.3 kb 
PCR fragment is diagnostic for dt clones (lower). (c) Cre-mediated recombination. trans-
targeted dt clones generated hypoxanthine aminopterin thymidine (HAT)-resistant (H
R
), 
G
R
, P
R
 df/dp clones. 
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Figure 3 D. Myc
dp/+
 and Pvt1-Gsdmc
dp/+
 mice do not display mammary gland 
hyperplasia. 
Whole mount analysis of mammary glands from 10 weeks-old Myc-Gsdmc
dp/+
, Pvt1-
Gsdmc
dp/+
, Myc
dp/+
 and wt virgin mice. The bottom panel shows images in higher-
magnification. Branch points were enumerated at a 25 mm
2
 area near the lymph node. 
Data are presented as mean ± standard error (SE). Significance at *p < 0.05, **p < 0.01 
and, ***p <0.001 using two-tailed Student’s t-test.  
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were examined for lateral branching and compared to those from Myc-Gsdmc
dp/+ 
mice 
(Figure 3D). At 10 weeks, careful enumeration and statistical analysis of branch points 
revealed that both Myc
dp/+ 
and Pvt1-Gsdmc
dp/+ 
mammary ducts had significantly less 
lateral branching compared to what we observed in Myc-Gsdmc
dp/+ 
mammary ducts 
(Figure 3D). Indeed, the lateral branching in mammary glands from Myc
dp/+ 
and Pvt1-
Gsdmc
dp/+ 
mice were similar to that observed in wild-type mice (Figure 3D). These data 
suggest that neither gain of Myc nor Pvt1-Gsdmc was sufficient to produce excessive 
mammary branching in mice.  
We then asked whether an extra copy of Myc or Pvt1-Gsdmc would be sufficient 
to cause aberrant proliferation in the mammary ducts. Mammary glands from 10 week-
old Myc
dp/+
,
 
Pvt1-Gsdmc
dp/+
, Myc-Gsdmc
dp/+
,
 
and wild-type mice were assayed for 
proliferation using BrdU. No incorporation of BrdU was found in wild-type, Myc
dp/+
, and
 
Pvt1-Gsdmc
dp/+
mammary ducts, whereas, consistent with our previous finding, we 
observed a significant increase in BrdU incorporation in Myc-Gsdmc
dp/+
 ducts (Figure 
3E). These data indicate that Myc and Pvt1-Gsdmc synergize to mediate excessive lateral 
branching morphology and aberrant cellular proliferation in mammary ducts. To test the 
hypothesis of this excessive lateral branching structural aberration was caused by 
increased copy number gain of Myc-Gsdmc interval, we evaluated the phenotype of 
mammary glands from 10 weeks-old Myc-Gsdmc
dp/df
 mice. Myc-Gsdmc
dp/df
 mammary 
tissue exhibited normal mammary development (Figure 3F). There is no significant  
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Figure 3 E. Neither Myc nor Pvt1 alone are sufficient to inhibit proliferation arrest. 
Immunofluorescence images of BrdU incorporation in mammary ducts of wild type, 
Myc-Gsdmc
dp/+
, Pvt1-Gsdmc
dp/+
, Myc
dp/+ 
mice. Antibodies against BrdU (red) and K14 
(green) were used. Quantification of BrdU positive cells represented as a percentage of 
the total DAPI (blue) stained nuclei. (n=5 for each genotype, ***p<0.001). 
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increase in mammary ductal branching and BrdU-positive cells of the Myc-Gsdmc
dp/df
 
mammary glands compared with wild-type mice (Figure 3F and 3G), demonstrating that 
these aberrant phenotypes are due to increased dosage of Myc-Gsdmc interval. 
 
Single Copy Gain of Myc-Gsdmc is an Oncogenic Aberration which Promotes 
Mouse Mammary Tumors 
Human cancers with gain of 8q24.21 have been reported to express a high level of 
PVT1 transcripts (Haverty et al., 2009). To examine whether the genomic rearrangements 
in our three mouse models affect the expression of genes in the Myc-Gsdmc interval, we 
carried out real-time, quantitative reverse transcription-PCR (RT-qPCR) analysis using 
total RNA isolated from mammary glands of Myc-Gsdmc
dp/+
, Myc
dp/+ 
and Pvt1-Gsdmc
dp/+
 
mice (virgin, 10 weeks of age). The level of Myc transcripts was approximately 2.7 (± 
0.7) fold higher in Myc-Gsdmc
dp/+
 and Myc
dp/+
 mammary glands compared to the wild-
type, while no change was found in the Pvt1-Gsdmc
dp/+
 mice (Figure 4A). Interestingly, 
the Pvt1 transcripts were elevated in Myc-Gsdmc
dp/+
 and Myc
dp/+
 mammary glands, but 
not in Pvt1-Gsdmc
dp/+
.  Mammary glands of all these mice showed negligible expression 
of Gsdmc (Appendix B).  We also assayed the protein levels of Myc in the mammary 
glands of these mice by western blotting (Figure 4B) and found it to be increased 3 (± 
0.3) times higher in Myc-Gsdmc
dp/+
, compared to Myc
dp/+ 
or Pvt1-Gsdmc
dp/+
 mammary 
glands (Figure 4B). This suggests that the gain of one more copy of the Myc-Gsdmc 
interval leads to increased Myc protein in  
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Figure 3 F. Myc-Gsdmc
df/dp
 mammary ducts are as normal as wt. 
Whole mount analysis of mammary glands from 10 weeks-old Myc-Gsdmc
dfdp
 and wt 
virgin mice. Quantification of ductal branch points per 25 mm
2
 area shown as bar graph. 
Data are presented as mean ± standard error (SE), n=3 for each genotype. 
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Figure 3 G. Myc-Gsdmc
df/dp
 mammary epithelial cells (MECs) are quiescent. 
Immunofluorescence images of BrdU incorporation in mammary ducts from 10 weeks-
old virgin Myc-Gsdmc
df/dp
 mice and wt mice. Antibodies against BrdU (red). DAPI 
stained nuclei in blue. Quantification of BrdU positive cells represented as a percentage 
of the total DAPI (blue) stained nuclei. (n=3 for each genotype). 
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Figure 4 A. Quantitative RT-PCR analysis to assess the relative expression of Myc, 
Pvt1, and Gsdmc mRNA in mammary glands. 
RT-qPCR analysis of Myc, Pvt1 and Gsdmc in mammary glands of wild type, Myc-
Gsdmc
dp/+
, Pvt1- Gsdmc
dp/+
 and Myc
dp/+
 mice. Mammary glands were isolated from 10 
weeks-old virgin mice. n=3 for each genotype. * p < 0.05, ** p < 0.01. ND, not detected 
because of low expression.  
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Figure 4 B. Western analysis of total protein lysates from mammary glands of 
indicated genotypes. 
The relative densities of c-Myc and p53 were calculated by normalizing against the 
GAPDH intensities, and of p-ERK1/2 by normalizing against total ERK protein levels for 
each genotype. Data are presented as mean ± standard error (SE), n=3 for each genotype. 
* p < 0.05.  
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mammary glands. However, single-copy gain of Myc alone does not result into increased 
Myc protein. 
A possible consequence of increased Myc protein levels is activation of pro-
survival pathways that could explain the unregulated proliferation seen in Myc-Gsdmc
dp/+
 
mammary ducts.  We carried out western blot analysis of total protein isolated from the 
mammary glands of Myc-Gsdmc
dp/+
, Myc
dp/+
, Pvt1-Gsdmc
dp/+
,
 
and wild type mice for 
pro-survival signaling. Indeed, phospho-ERK1/2 levels were 4.2 (± 1.6) fold elevated in 
Myc-Gsdmc
dp/+
 mammary epithelium (Figure 4B), suggesting up-regulation of ERK1/2 
signaling in the Myc-Gsdmc
dp/+
 mammary gland but not in Myc
dp/+ 
or Pvt1-Gsdmc
dp/+
. An 
increased level of Myc protein should also result in an oncogene-induced DNA-damage 
response (Vafa et al., 2002) . We observed a 3.0 (± 0.7) fold enrichment of p53, a key 
mediator of cellular stress response, in total protein lysates from Myc-Gsdmc
dp/+
 
mammary glands compared to Myc
dp/+ 
or Pvt1-Gsdmc
dp/+
 (Figure 4B). Because p53 is a 
pro-apoptotic protein, we carried out a terminal deoxynucleotidyl transferase-dUTP nick-
end-labeling (TUNEL) assay to determine the degree of apoptosis in Myc-Gsdmc
dp/+
, 
Myc
dp/+
, Pvt1-Gsdmc
dp/+
, and wild type mammary gland sections. We detected more 
TUNEL- positive cells in Myc-Gsdmc
dp/+
 mammary glands (1.7% ± 0.5) indicating 
increased cellular apoptosis due to elevated levels of Myc protein (Figure 4C). A critical 
feature of oncogene induced DNA damage response is the formation of γ-H2AX foci at 
the site of the DNA damage. Enhanced oncogene-induced DNA-damage response in 
Myc-Gsdmc
dp/+
 mammary ducts was evident by the increased number of foci  
 57 
 
  
 
Figure 4 C. Increased apoptosis in mammary ducts of Myc-Gsdmc
dp/+
 mice. 
TUNEL assay was carried out on the mammary sections from wt, Myc-Gsdmc
dp/+
, 
Myc
dp/+
, and Pvt1- Gsdmc
dp/+
  mice. Antibody against myoepithelial marker K14 (red) 
and TUNEL positive cells (green) are shown. DAPI (blue) used as counterstain. Three 
mice for each genotype was used. Nine mammary ducts for each mouse were examined. 
Arrows indicate TUNEL positive cell (green). Quantification of the number of TUNEL 
positive cells as a percentage of the total number of cells represented in bar graph, mean 
± SE, *P < 0.05. 
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containing phosphorylated- γ-H2AX (160 foci per 100 ducts) compared those in Mycdp/+ 
and Pvt1-Gsdmc
dp/+
 mice (30 – 40 foci per 100 ducts) (Figure 4D). These data suggest 
that a single copy gain of the Myc-Gsdmc interval can lead to increased Myc protein 
levels resulting oncogenic activation by pro-survival signaling and DNA-damage 
response. 
 The above experiments indicated that gain of Myc-Gsdmc may predispose cells to 
tumorigenesis, while gain of either the Myc or Pvt1-Gsdmc alone is insufficient to do so. 
In breast and ovarian cancer, gain of 8q24 has been reported to be co-incident with 
amplification of ERBB2/HER2 in chromosome 17q12 (Al-Kuraya et al., 2004; Korkola 
and Gray; Park et al., 2005). About 40% of HER2-positive breast cancers have gain of 
the 8q24 locus, suggesting co-mutations of these two loci in some cancer patients (Perez 
et al., 2011; Sircoulomb et al., 2010). Patients with breast cancer who had gain of 8q24 
with concurrent amplification of HER2 were observed to have substantially worse 
outcomes than patients who had only amplification of HER2 (Al-Kuraya et al., 2004). 
We crossed  Myc-Gsdmc
dp/+
, Myc
dp/+ 
and Pvt1-Gsdmc
dp/+ 
with mice harboring an un-
activated neu (rat) transgene under the transcriptional control of the mouse mammary 
tumor virus promoter/enhancer (MMTV-neu/+,(Guy et al., 1992) (Figure 4E). To 
investigate the contribution of Myc-Gsdmc gain in mammary epithelial transformation, 
we carried out 3-D culture analysis of MECs isolated from 10 weeks old MMTV-neu/+ 
and Myc-Gsdmc
dp/+
, MMTV-neu/+ mice. At day 14, we found that 71.8% (± 1.4) of the 
Myc-Gsdmc
dp/+
, MMTV-neu/+ MECs displayed transformed acinar phenotypes in 3-D 
culture, compared to only  
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Figure 4 D. IF staining for γ-H2AX foci. 
Fluorescence images of γ-H2AX foci formation in mammary epithelium (in red). One 
hundred ducts from each genotype were examined. The bar graph represents cumulative 
numbers of γ-H2AX foci from each genotype. n=3 for each genotype. Significance at **p 
< 0.01 using two-tailed Student’s t-test. 
 60 
 
 
 
Figure 4 E. Generation of mouse with double mutations by crossing the duplication 
and MMTVneu lines. 
Schematic of generating the Myc-Gsdmc
dp/+
,MMTV-neu/+, Pvt1-Gsdmc
 dp/+
,MMTV-
neu/+, and Myc
 dp/+
,MMTVneu/+ mice. 
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48.5% (± 2.3) of the MMTV-neu/+ MECs (Figure 4F). We also performed transwell 
migration assays to determine the migratory response of these MECs to different 
concentrations of epidermal growth factor (EGF). Myc-Gsdmc
dp/+
, MMTV-neu/+ MECs 
exhibited nearly twice the migratory response to EGF compared to MMTVneu/+ cells 
(Figure 4G). These in vitro studies suggest that a single-copy gain of the Myc-Gsdmc
 
interval may contribute to increased neoplastic transformation in the Myc-Gsdmc
dp/+
, 
MMTV-neu/+ MECs. To determine the effect of Myc-Gsdmc gain in cellular 
transformation in vivo, we carried out a whole-mount analysis of mammary glands from 
14 week old Myc-Gsdmc
dp/+
, MMTV-neu/+ and MMTV-neu/+ mice. Myc-Gsdmc
dp/+
, 
MMTV-neu/+ mammary glands revealed structures that looked consistent with 
hyperplastic alveolar nodules (HAN) which were not found in MMTV-neu/+ mice 
(Figure 4H). Usually, HAN structures are precancerous lesions found in neoplastic 
mammary glands (Harkness et al., 1957).  Taken together, these data provided strong 
evidence in support of our hypothesis that Myc-Gsdmc gain could predispose mammary 
epithelium for oncogenic transformation. 
We carried out a mammary tumor latency study using 1) Myc-Gsdmc
dp/+
, MMTV-
neu/+; 2) Myc
dp/+
, MMTV-neu/+; 3)
 
Pvt1-Gsdmc
dp/+
, MMTV-neu/+; and 4) MMTV-
neu/+ mice.
 
 Mice with mean tumor diameters of 1 cm were enrolled for tumor onset. The 
log-rank test was performed on the Kaplan–Meier tumor-free curves. The Myc-
Gsdmc
dp/+
, MMTV-neu/+ mice showed 90% penetrance of mammary tumors with a 
median latency of 224 days. In comparison, only half of  
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Figure 4 F. Myc-Gsdmc
dp/+
, MMTVneu/+ MECs exhibit increased number of 
abnormal acinar structure than MMTVneu/+ MECs in 3-D culture.  
c-Myc-Gsdmc
dp/+
, MMTVneu/+ and MMTVneu/+ MECs were grown for 14 days in 3-D 
Matrigel cultures. Representative DIC images of normal and abnormal acinar structures 
are shown in the top panel. 200 acinar structures of each genotype were examined in a 
double blinded study. Number of acini exhibiting abnormal features for each genotype 
were scored. Data presented as mean ± SE, ***P< 0.001. 
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Figure 4 G. Transwell migration assay shows the MMTVneu/+, Myc-Gsdmc
dp/+
 
mammary epithelial cells has a higher migratory ability to EGF compared to the 
MMTVneu cells.  
Primary mammary epithelial cells were isolated from mammary glands of MMTVneu, 
Myc-Gsdmc
dp/+
 or MMTVneu virgin littermates at ages of 12 weeks. Equal amount of 
MMTVneu, Myc-Gsdmc
dp/+
 and MMTneu cells were plated in the top chamber with the 
non-coated membrane. Cells were plated in medium without serum and growth factors, 
and medium supplemented with EGF was used as a chemoattractant in the lower chamber 
for 24 hr incubation. (Top panel) Bright-field images of MMTVneu, Myc-Gsdmc
dp/+
 and 
MMTVneu cells stained with hymatoxyline to measure migratory cells. Four bright-field 
images were taken of each transwell membrane. Magnification, 200X. (Lower panel) 
Quantitative representation of migratory cell numbers from each field. Data are presented 
as mean ± SE, **, P < 0.005. 
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Figure 4 H. Early onset of hyperplastic alveolar nodules (HAN) like structures in 
MMTVneu/+, Myc-Gsdmc
dp/+
 mammary glands.   
Whole mount preparations of mammary glands from 14 weeks old virgin MMTVneu/+ 
and MMTVneu/+, Myc-Gsdmc
dp/+
 are compared. The inset in the lower panel shows the 
HAN like structure in the MMTVneu/+, Myc-Gsdmc
dp/+
  mammary glands. 
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the Myc
dp/+
, MMTV-neu/+;
 
and MMTV-neu/+ cohorts developed mammary tumors at a 
median latency of 345 days (Figure 4I). Neither Myc
dp/+
, MMTV-neu/+ nor
 
Pvt1-
Gsdmc
dp/+
, MMTV-neu/+mice exhibited abbreviated latency in mammary tumorigenesis 
similar to Myc-Gsdmc
dp/+
, MMTV-neu/+. These results stroungly suggest co-operation 
between Myc and other potential genes or regulatory sequences in the Myc-Gsdmc 
interval contribute to the reduced latency of mammary tumorigenesis. The Myc-
Gsdmc
dp/+
, MMTV-neu/+  tumors presented a spectrum of morphologies from poorly 
encapsulated, solid, nodular, masses (Fig 4J) to solid masses containing pools of 
eosinophilic secretory material, to more differentiated masses with alveoli containing 
secretory material.  Additional features included a high mitotic index (Fig 4J-b, arrow) 
particularly involving the solid masses, or variably sized areas of necrosis.  Some of these 
masses were locally invasive, or in places invaded adjacent thin walled blood vessels (Fig 
4J-a, arrow) consistent with adenocarcinomas. These data strongly indicate that gain of 
just one copy of the Myc-Gsdmc region is an oncogenic aberration and can drive early 
tumorigenesis in mouse mammary glands. 
 
Non-coding RNA PVT1 Controls Cellular Proliferation in Mammary Tumors  
It is evident from the above experiments that Myc co-operates with other genes in 
the Myc-Gsdmc interval in the neoplastic transformation of Myc-  
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Figure 4 I. Kaplan–Meier analysis of mammary tumor free among the different 
genotypes.  
Highly significant difference (*** p < 0.001, logrank test) in the tumor latency between 
Myc-Gsdmc
dp/+
,MMTV-neu/+ and the other genotypes. 
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Figure 4 J. Representative histopathology of mammary tumors from Myc-
Gsdmc
dp/+
,MMTV-neu/+ mice.  
Panel a shows a solid, expansile tumor that is invading a small blood vessel (arrow), bar 
= 1000 μm. Panel b shows numerous mitotic figures (arrows), bar = 100 μm. 
  
a b 
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Gsdmc
dp/+
, MMTV-neu/+ mammary epithelium. Since the Myc-Gsdmc interval is a gene 
desert region and Gsdmc transcripts were barely detectable in mouse mammary glands, 
we investigated the possible role of Pvt1 in the Myc-Gsdmc
dp/+
, MMTV-neu/+ mammary 
tumors. We reasoned that if Myc or Pvt1 is contributing to the neoplastic transformation 
of Myc-Gsdmc
dp/+
, MMTV-neu/+ cells, then depleting either Myc or Pvt1 will result 
reduction in proliferation of these cells. Two independent tumors, YYT 549-t and YYT 
402-t, each of 1-cm diameter were harvested from Myc-Gsdmc
dp/+
, MMTV-neu/+ mice. 
Cells isolated from these tumors were grown in 2-dimensional (2-D) culture for 2-3 days. 
Transfection of these tumor cells was carried out with respective si-RNAs to knockdown 
either Myc (si-Myc), Pvt1 (si-Pvt1), or both (si-Myc + si-Pvt1) (Figure 5A). The 
transfection efficiencies of the si-RNAs were monitored by fluorescent emission of Alexa 
488, which was conjugated with a control si-RNA. We obtained at least 90% transfection 
efficiency in these cells growing in 2-D culture for 16 hrs (data not shown). These cells 
were then grown in 3-D culture for 72 hrs, stained for proliferative marker Ki67, and the 
proliferating cells were enumerated (Figure 5A). Depletion of Pvt1 resulted in 55% 
reduction in proliferation in these cells (percentage of Ki67 positive cells - YYT549-t: 
43.3 ± 2.5%, YYT402-t: 47.5 ± 8.9%) (Figure 5B). Similarly, knock down of Myc led to 
65% decrease in the Ki67 positive Myc-Gsdmc
dp/+
, MMTV-neu/+ cells compared to the 
control (YYT549-t: 34.9 ± 1.8%, YYT402-t: 37.7 ± 3.3%) (Figure 5B). This conclusively 
shows that both Pvt1 and Myc contribute to the proliferation of Myc-Gsdmc
dp/+
, MMTV-
neu/+ tumors. Surprisingly, knock down of both Myc and Pvt1 in the Myc-Gsdmc
dp/+
,  
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Figure 5 A. Schematic of proliferation assay for Myc-Gsdmc
dp/+
, MMTV-neu/+ 
mammary tumor derived cells obtained from two mice, YYT549 and YYT409. 
Cells were transfected with siRNA against Myc (si-Myc), Pvt1 (si-Pvt1), and Ctrl (si-
Ctrl). Transfection efficiency was confirmed by si-Ctrl conjuigated with Alex-488 
(green). After growing the transfected cells in 3-D culture system, the cells were stained 
using antibody against Ki-67. Images were taken under the microscope (magnification 
×20). 
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Figure 5 B. Ki-67 proliferation indexes from siRNA mediated silencing of Myc, 
Pvt1, and Myc+Pvt1 in primary mammary tumor cells. 
Quantification of the number of cells undergoing proliferation in 3-D culture is measured 
by their Ki-67 index. n = 3 for each transfected cell line (top: YYT549, bottom: 
YYT402). Significance at **p < 0.01 and, ***p <0.001 using two-tailed Student’s t-test. 
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MMTV-neu/+ tumor cells led to an identical (YYT549-t: 39.2 ± 3.2%, YYT402-t: 40.7 ± 
1.4%) decreases in proliferation as observed when either Myc or Pvt1 was  
knocked down separately (Figure 5B). We verified the specificity and the efficiency of 
the si-RNAs by RT-qPCR analysis of Myc and Pvt1 in these cells (Figure 5C). Knocking 
down Myc or Pvt1 transcripts with their respective si-RNAs were specific and did not 
affect the transcript levels of the other, or vice versa (Figure 5C). From these data we 
inferred that Myc and Pvt1 were mediating their oncogenic activity through the same 
pathway, which may explain why depletion of Myc and Pvt1 together would result in 
identical proliferative inhibition in Myc-Gsdmc
dp/+
, MMTV-neu/+ tumor cells as when 
they are knocked down separately.  
To determine if PVT1 has a similar role in human breast cancers, we carried out 
identical experiments in human breast cancer cell lines that have a gain of 8q24.21. 
Breast cancer cell lines SK-BR-3 and MDA-MB-231 harbor copy number gains of 
8q24.21 (Guan et al., 2007; Huppi et al., 2008). We knocked down either MYC (si-MYC) 
or PVT1 (si-PVT1) or both (si-MYC + si-PVT1) in SK-BR-3 and MDA-MB-231 as 
described above. The transfection efficiency in each cell line was optimized using a 
control si-RNA with Alexa 488. Under the conditions in which at least 90% transfection 
efficiency was achieved (Figure 5D), the cell lines were transfected with si-MYC, si-
PVT1, or si-MYC + si-PVT1. The cells were allowed to grow in 2-D for 16 hrs, 
following which they were plated on 3-D Matrigel
TM
 and allowed to grow for 72 hrs. As 
before, the Ki67 index for each cell line was taken as a measure of its proliferative 
potential. In SK-BR-3, proliferation was reduced by 29.4% (± 0.9), 37.3 % (± 5), and 
29.3% (±  
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Figure 5 C. Quantitative RT-PCR analysis to assess the relative expression of Myc, 
Pvt1, and Gsdmc mRNA in primary mammary tumor cells after siRNA mediated 
silencing.  
Relative mRNA expression of Myc, Pvt1 and Gsdmc in Myc-Gsdmc
dp/+
, MMTV-neu/+ 
mammary tumor cells transfected with the si-RNAs. ND, not detected because of low 
expression. Significance at ***p <0.001 using two-tailed Student’s t-test. 
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Figure 5 D. Ki-67 proliferation indexes from siRNA mediated silencing of MYC, 
PVT1, and MYC+PVT1 in human breast cancer cells. 
Proliferation assay of human breast cancer cell lines SK-BR-3 (top) and MDA-MB-231 
(bottom) growing in 3-D culture after the cell lines were transfected with si-Ctrl, si-
MYC, si-PVT1 and (si-MYC + si-PVT1). Transfection in each cell line was confirmed as 
mentioned in (A). n = 3 for each transfected cell line. Significance at **p < 0.01 and, 
***p <0.001 using two-tailed Student’s t-test. 
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4.7) in cells transfected with si-MYC, si-PVT1, and si-MYC + si-PVT1 respectively 
(Figure 5D). Similarly, for MDA- MB-231 cells transfected with si-MYC, si-PVT1, and 
si-MYC + si-PVT1, reduction in Ki67 index was observed by 33.8% (± 5.4), 28.9% (± 
4.6) and 31.9% (± 3.2) respectively (Figure 5D). Once again, we found the similar level 
of proliferation arrest in both the cell lines with reduced levels of MYC, PVT1, or MYC + 
PVT1. Efficiency and specificity of the si-RNAs in reducing the MYC, PVT1, or 
MYC+PVT1 transcript levels were confirmed by RT-qPCR in both the cell lines (Figure 
5E). These data suggest that PVT1 and MYC can control proliferation of mouse and 
human breast cancer cell lines through a shared pathway.  
 
PVT1 Regulates MYC Stability in Human Breast Cancer 
An Increase in Myc protein level in the Myc-Gsdmc
dp/+
 mammary glands was 
found (Figure 4B) with concomitant increases in Pvt1 transcripts. To investigate whether 
a similar correlation could be observed in the human breast cancer cell lines with 
8q24.21-gain, we quantified the levels of PVT1 transcripts and MYC protein in SK-BR-3 
and MDA-MB-231 cell lines and compared them with untransformed breast cell line 
MCF-10A. RT-qPCR analysis revealed that PVT1 transcript was enriched 6.2-fold (± 0.3) 
in SK-BR-3 cells and 15.7-fold in MDA-MB-231 cell lines compared to the level of 
PVT1 in MCF-10A (Figure 6A).  Using Western blot analysis, we also detected a higher 
protein level of MYC in SK-BR-3 and MDA-MB-231 cell lines compared to MCF-10A 
(Figure 6B). This  
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Figure 5 E. Quantitative RT-PCR analysis to assess the relative expression of MYC, 
PVT1, and GSDMC mRNA in human breast cancer cells after siRNA mediated 
silencing. 
Relative mRNA expression of MYC, PVT1, and GSDMC in SK-BR-3 (top) and MDA-
MB-231 (bottom) breast cancer cells transfected with the respective si-RNAs. Each bar 
represents the mean ± SE of triplicate experiments. ** p < 0.01, *** p < 0.001. 
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Figure 6 A. Quantitative RT-PCR analysis to assess the relative expression of MYC, 
PVT1, and GSDMC mRNA in human breast cancer cells. 
Relative expression of MYC, PVT1 and GSDMC transcripts in SK-BR-3 and MDA-MB-
231 (with 8q24 gain) and MCF10A (without 8q24 gain). Significance at *p < 0.05 and, 
***p <0.001 using two-tailed Student’s t-test. 
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Figure 6 B. SK-BR-3 and MDA-MB-231 cells express higher level of MYC protein 
compared to MCF10A. 
Western analysis for MYC expression in MCF10A, SK-BR-3, and MDA-MB-231 cell 
lines. 
  
 78 
 
observation corroborates with our finding that Pvt1 transcript and Myc protein are 
increased in mouse mammary epithelia with a gain of the Myc-Gsdmc interval. In 
addition, functional analyses of Myc-Gsdmc
dp/+
, MMTV-neu/+ mammary tumors as well 
as in human cancer cell lines SK-BR-3 and MDA-MB-231, PVT1 and MYC seemed to 
control proliferation via same pathway (Figure 5B and 5D). Accordingly, we 
hypothesized that PVT1 regulates MYC protein levels in the SK-BR-3 and MDA-MB-
231 cell lines. To address this, we knocked down MYC (si-MYC), PVT1 (si-PVT1) or 
both (si-MYC + si-PVT1) in SK-BR-3 and MB-MDA-231 cell lines. Western blot 
analyses showed that a depletion of PVT1 led to strong reduction of MYC protein in SK-
BR-3 (35.7 ± 7.4%) and in MB-MDA-231(61.9 ± 3.5%) (Figure 6C). These data suggest 
that the PVT1 co-operates with MYC in these human breast cancer cell lines by 
regulating its protein level.  
Because the depletion of PVT1 did not affect the MYC mRNA level (Figure 5E), 
we investigated whether PVT1 regulates MYC protein level in these cells by modulating 
its stability.  A recent study has shown that Myc half-life is significantly longer in SK-
BR-3 cell line, ranging from 80 to 90 minutes, compared to MCF10A, which ranged from 
16 to 20 minutes (Zhang et al., 2012). SK-BR-3 cells were transfected with si-PVT1 for 
16 hrs and were treated with 10 μM of cycloheximide, a protein synthesis inhibitor, for 0, 
15, 30, 45 and 60 minutes. A non-specific si-RNA (si-Ctrl) was used as a control. 
Following the cycloheximide treatment, both si-PVT1 and si-Ctrl transfected cells were 
harvested at the above mentioned time points and whole cell lysates were subjected to 
Western blot analysis for MYC and GAPDH. We observed a rapid degradation of MYC 
in  
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Figure 6 C. Western analysis for MYC protein in the total lysates obtained from 
SK-BR-3 and MDA-MB-231 cell lines transfected with different si-RNAs. 
The relative density for each category was determined by normalizing against the 
intensity of the GAPDH band. Data are presented as mean ± standard error (SE). 
Significance at *p < 0.05, **p < 0.01 and, ***p <0.001 using two-tailed Student’s t-test. 
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Figure 6 D. PVT1 regulates MYC stability in SK-BR-3 breast cancer cells. 
Stability of c-MYC protein in SK-BR-3 transfected with si-Ctrl and si-PVT1 and treated 
with 10 μM cycloheximide (CHX) for different time points (top row). The relative 
density was determined by comparing against the GAPDH level (bottom row). Each bar 
represents the mean ± SE of triplicate experiments. * p < 0.05, ** p < 0.01, *** p < 
0.001. 
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PVT1 depleted cells (si-PVT1) compared to the control (si-Ctrl) after cycloheximide 
treatment (Figure 6D). A quantitative analysis revealed that 45.7% of MYC was degraded 
at the 30 minutes time point after cycloheximide treatment in PVT1 depleted cells, while 
88.5% of the MYC protein was still intact in si-Ctrl transfected cells. Taken together, 
these results provide strong evidence that PVT1 regulates MYC protein stability in human 
breast cancer cells with 8q24.21 gain. 
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Discussion 
There are several important findings in this study. First, we found that gain of a 
single copy of an approximately 2Mb gene-desert on 8q24 can lead to oncogenesis. In 
mammary tissues of Myc-Gsdmc
dp/+
 mice, we observe striking anomalies in mammary 
duct morphology that includes increased lateral branching and failure to undergo 
replicative quiescence in post- pubertal virgin females.  The mammary epithelial cells of 
these mice show abnormal differentiation and readily co-operate with Neu to undergo 
transformation. Low copy-number gain of 8q24, which includes PVT1, has been observed 
in several cancers including sarcomas (Hattinger et al., 2002; Zielenska et al., 2001) 
(Afify and Mark, 1999) (Sandberg and Bridge, 2002), prostate cancer (Chen et al.; 
Lapointe et al., 2007; Sato et al., 1999), colorectal cancer (Douglas et al., 2004; Liu et al., 
2007; Nakao et al.), cervical cancer (Zhang et al., 2002), medulloblastoma (Zitterbart et 
al., 2011), glioblastoma (Nishizaki et al., 1998), ovarian cancer (Noack et al., 2004; 
Osterberg et al., 2009), esophageal adenocarcinoma (Rygiel et al., 2008), small cell lung 
carcinoma (Kang et al., 2008; Yamada et al., 2000), hepatocellular carcinoma (Chochi et 
al., 2009; Wang et al., 2001) and acute myeloid leukemia (AML) (Grimwade et al., 1998; 
Le Beau et al., 2002). In human breast cancers, low copy-number gain of the 8q24 region 
is found in 15% of the patients (Chin et al., 2006; Guan et al., 2007; Liao and Dickson, 
2000) and is associated with poor prognosis (Bergamaschi et al., 2006; Borg et al., 1992). 
It has also been suggested that a difference in high versus low copy-number gains in 8q24 
may contribute to differences in clinico-pathological parameters in ovarian cancer 
(Dimova et al., 2006). Moreover, tumors in several genetically engineered mouse models 
for cancer develop spontaneous low copy-number gains, including trisomy of whole or 
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part of chromosome 15 that is syntenic with Hu 8q24. In the mouse model for acute 
promyelocytic leukemia (APL), in which tumor formation is driven by a PML-RARα 
fusion gene in the myeloid cells, 64% of the tumor bearing mice are found to harbor 
trisomy of chromosome 15 that is syntenic to Hu8q24 (Jones et al., 2010; Le Beau et al., 
2002). Mice harboring a hypomorphic allele of Dnmt1, which develop early onset of T 
lymphoma, also exhibit gain of chromosome 15 at high frequency (10 out of 12) (Gaudet 
et al., 2003).  Our results functionally verify these observations and suggest that gain of a 
single copy of 8q24 can predispose cells for transformation.  
Secondly, our data suggest that gain of just one copy of Myc is insufficient to 
drive tumorigenesis. Rather, oncogenesis requires co-operation from other participants in 
the 8q24 region. Though MYC has been considered the best candidate for cancer in the 
8q24 region, emerging evidences indicate other functional elements in the region that can 
influence the pathological outcome. For example, Myc-335 mice with deletion of a 
genomic region containing rs6983267, a common SNP found in several cancers and 
located 500 kb upstream of Myc, have been reported to be resistant to APCmin driven 
intestinal cancer (Sur et al., 2012). The gene-desert region surrounding MYC may harbor 
several unidentified candidates which can facilitate tumor pathophysiology. Our mouse 
strains provide a mechanistic understanding of co-operation between multiple genes in 
the 8q24.21 ‘gene desert’ locus and advances our knowledge regarding a poorly 
understood mutation which is common in all major cancers. Copy-number gain of 8q24 
in human cancers presents a characteristic challenge in understanding the functional 
consequences associated with structural variations in human cancer. Although MYC is the 
most prominent gene in this region and garners obvious attention, the role of the genomic 
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segments adjoining MYC that are also co-amplified in almost every cancer remains 
unexplained. Our results unequivocally show that in addition to Myc, an additional gene 
in the Myc-Gsdmc locus, the Pvt1  non-coding RNA,co-operate to drive cellular 
transformation when this region is gained. We observed up regulation of pro-survival 
pathways as well as increased DNA damage response in the Myc-Gsdmc
dp/+
, but not in 
Myc
dp/+
 or Pvt1-Gsdmc
dp/+
 mammary tissues. This suggests that gain of Myc-Gsdmc can 
result in sufficient activation of oncogenic events necessary for tumorigenesis, namely 
activation of cellular stress markers and pro-survival pathways that cannot be mediated 
by single-copy gain of Myc alone.  
This co-operative activity may have important implications in our understanding 
of the mechanisms underlying cellular transformation in the cancer cells where 8q24 is 
gained. Known to be genomically unstable, this region is considered to be a hot spot to 
undergo structural mutations (Huppi et al., 2008). Our work demonstrates that a simple 
duplication of about 2 Mb in this region renders the cell vulnerable to cellular 
transformation. It has been previously speculated that changes caused by gain of human 
8q24 or the corresponding locus in mouse chromosome 15, such as increased copy-
number of TRIB1, PVT1, CCDC26 and other genes in this region may impact 
tumorigenesis in collaboration with MYC (Guan et al., 2007; Jones et al., 2010; Radtke et 
al., 2009; Rothlisberger et al., 2007). Tumorigenesis facilitated by gain of Myc-Gsdmc, 
which encompasses, in addition to MYC, the genomic locus syntenic to PVT1 and 
CCDC26 in the human, and harbors several risk alleles found in human cancers, is a 
direct proof of this hypothesis. Though we have identified Pvt1 as an oncogene that co-
operates with Myc in the tumors in the Myc-Gsdmc
dp/+
,MMTV-neu/+ mice, it is possible 
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that other functional elements in the Myc-Gsdmc region can also play a role in the 
tumorigenesis. Thus, these mice will be useful as functional models to illuminate the 
importance of 8q24.21 in tumorigenesis.  
Thirdly, we identified a novel role of a lncRNA in 8q24, PVT1, in tumorigenesis 
and regulation of MYC in human breast cancer cells. Knock-down of PVT1 reduced 
proliferation of Myc-Gsdmc
dp/+
,MMTV-neu/+ tumor cells as well as in human breast 
cancer cell lines, SK-BR-3 and MDA-MB-231. Additionally, since knock-down of either 
MYC, PVT1, or both resulted in similar reduction in proliferation, we reasoned that PVT1 
and MYC affect the same oncogenic pathway. The presence of increased Myc protein in 
Myc-Gsdmc
dp/+
, but not in Myc
dp/+
 or Pvt1-Gsdmc
dp/+
 mammary epithelial cells led us to 
conclude that Pvt1 can regulate Myc levels in these cells, thereby sensitizing them for 
transformation. This was supported by knocking down PVT1 which resulted in reduction 
of MYC in both SK-BR-3 and MDA-MB-231.   
PVT1 is a lncRNA with unknown function. It is a hotspot for translocation that 
has been observed in many cancers including Burkitt’s lymphoma (Graham and Adams, 
1986; Mengle-Gaw and Rabbitts, 1987), multiple myeloma (Nagoshi et al., 2012), and 
medulloblastoma (Northcott et al., 2012). Overexpression and/or gain of PVT1 and some 
of its miRNAs have been reported in several malignancies, including breast cancer and it 
has been suggested to contribute to suppression of apoptosis in these cells (Bakkus et al., 
1990; Beck-Engeser et al., 2008; Guan et al., 2007; Huppi et al., 1993; Huppi et al., 2008; 
Meyer et al.; Shtivelman and Bishop, 1989; Sugawara et al., 2011). Recently PVT1 has 
been reported to regulate gemcitabine-sensitivity in human pancreatic cells (You et al., 
2011) and to provide resistance to cyclolignan picropodophyllin (PPP), a new anticancer 
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drug with tumor-inhibitory effects (Hashemi et al., 2011). However, no mechanistic 
explanation for any of its functions has been reported. Here we show that PVT1 helps 
maintain MYC level in human breast cancer cells with gain of 8q24, thus establishing a 
feedback mechanism for MYC protein in these cancer cells. This can eventually cause the 
affected cells to be addicted to higher protein levels of MYC. Therefore, knocking down 
PVT1 in human breast cancer cell lines results in reduction of MYC protein. Surprisingly, 
PVT1 ablation leads to decreased stability of MYC in SK-BR-3 cells, providing a 
mechanistic insight to the co-operation of adjacent genes, MYC and PVT1, in cellular 
transformation. To our knowledge, this is the first data showing the role of a lncRNA in 
maintaining the MYC protein by regulating its stability in cancer cells.  
Additionally, we suggest that a detailed understanding of how PVT1 regulates 
MYC protein in cancer cells can be exploited therapeutically. Soucek et al. have shown 
that MYC ablation can result in apoptosis in cancer cells, but not in normal cells, and can 
cause regression of K-ras mediated lung cancer in mice (Soucek et al., 2008) thereby 
demonstrating the central importance of MYC in human cancer. However, so far it has 
not been possible to target MYC directly. Recent development of JQ1, a small molecule 
inhibitor of Bromodomain 4 has been found to indirectly inhibit MYC (Delmore et al., 
2011; Zuber et al., 2011). But although JQ1 has shown promise in blood-related cancers, 
it has not been effective in breast cancer. This example highlights the difference in 
contexts and the driver mutations that stabilize MYC in different cancers (Mertz et al., 
2011). Our findings suggest a novel mechanism by which PVT1 can contribute to MYC 
stability in breast cancers. We propose that PVT1 could be a potential target for inhibiting 
MYC in breast cancer for patients with gain of 8q24.  
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Appendix A: Synteny of MYC-GSDMC interval between human and mouse.  
The MYCGSDMC interval in human (a) and mouse (b) as represented in the UCSC 
genome browser (Feb. 2009, GRCh37/hg19 Assembly for human and Dec. 2011, 
GRCm38/mm10 Assembly for mouse).  
 
 
 
 
a 
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Appendix B: Reduced expression of Gsdmc transcript in mouse mammary tissue. 
Semi-quantitative RT-PCR of Gsdmc transcript in mouse colon and mammary tissues. 
PCR was carried out using equal amount of cDNAs derived from colon and mammary 
tissues, for cycles as indicated. NC indicates negative control (water). PCR using primers 
for β-actin carried out for 20 cycles. 
 
 
